UY39724A - Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un a - Google Patents
Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un aInfo
- Publication number
- UY39724A UY39724A UY0001039724A UY39724A UY39724A UY 39724 A UY39724 A UY 39724A UY 0001039724 A UY0001039724 A UY 0001039724A UY 39724 A UY39724 A UY 39724A UY 39724 A UY39724 A UY 39724A
- Authority
- UY
- Uruguay
- Prior art keywords
- combination
- antibody against
- treating
- malignant neoplasm
- prolgolimab
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere al uso del anticuerpo contra PD-1, en particular prolgolimab, en combinación con al menos un agente quimioterapéutico, en particular paclitaxel, carboplatino o cisplatino, para tratar una neoplasia maligna, y al uso del anticuerpo contra PD-1 prolgolimab en combinación con el anticuerpo contra VEGF, en particular bevacizumab, y al menos un agente quimioterapéutico, en particular paclitaxel, carboplatino o cisplatino, para tratar una neoplasia maligna.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2021109765A RU2787457C2 (ru) | 2021-04-08 | Способ лечения злокачественного новообразования с использованием комбинации антитела к pd-1 и химиотерапевтического агента |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39724A true UY39724A (es) | 2022-10-31 |
Family
ID=83546621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039724A UY39724A (es) | 2021-04-08 | 2022-04-08 | Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un a |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP4319736A1 (es) |
CN (1) | CN117500493A (es) |
AR (1) | AR125322A1 (es) |
BR (1) | BR112023020856A2 (es) |
CL (1) | CL2023003012A1 (es) |
CO (1) | CO2023013510A2 (es) |
EC (1) | ECSP23076237A (es) |
MA (1) | MA62924A1 (es) |
MX (1) | MX2023011952A (es) |
TW (1) | TW202304511A (es) |
UY (1) | UY39724A (es) |
WO (1) | WO2022216184A1 (es) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070119745A (ko) * | 2005-05-12 | 2007-12-20 | 화이자 인코포레이티드 | 수니티닙 말레이트를 사용하는 항암 병행 요법 |
WO2020226986A2 (en) * | 2019-05-03 | 2020-11-12 | Genentech, Inc. | Methods of treating cancer with an anti-pd-l1 antibody |
-
2022
- 2022-04-08 CN CN202280027483.7A patent/CN117500493A/zh active Pending
- 2022-04-08 BR BR112023020856A patent/BR112023020856A2/pt unknown
- 2022-04-08 WO PCT/RU2022/050122 patent/WO2022216184A1/en active Application Filing
- 2022-04-08 UY UY0001039724A patent/UY39724A/es unknown
- 2022-04-08 MX MX2023011952A patent/MX2023011952A/es unknown
- 2022-04-08 EP EP22785065.8A patent/EP4319736A1/en active Pending
- 2022-04-08 MA MA62924A patent/MA62924A1/fr unknown
- 2022-04-08 AR ARP220100896A patent/AR125322A1/es unknown
- 2022-04-08 TW TW111113464A patent/TW202304511A/zh unknown
-
2023
- 2023-10-06 EC ECSENADI202376237A patent/ECSP23076237A/es unknown
- 2023-10-06 CL CL2023003012A patent/CL2023003012A1/es unknown
- 2023-10-12 CO CONC2023/0013510A patent/CO2023013510A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2023003012A1 (es) | 2024-04-12 |
WO2022216184A1 (en) | 2022-10-13 |
AR125322A1 (es) | 2023-07-05 |
MX2023011952A (es) | 2023-11-09 |
BR112023020856A2 (pt) | 2024-02-06 |
CO2023013510A2 (es) | 2023-11-10 |
MA62924A1 (fr) | 2024-03-29 |
EP4319736A1 (en) | 2024-02-14 |
ECSP23076237A (es) | 2024-01-31 |
TW202304511A (zh) | 2023-02-01 |
CN117500493A (zh) | 2024-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020002914A1 (es) | Métodos y composiciones para tratar el cáncer | |
CO2017002081A2 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
UA116095C2 (uk) | Застосування пертузумабу, трастузумабу і хіміотерапії на основі карбоплатину для неоад'ювантного лікування her2-позитивного раку молочної залози ранньої стадії у пацієнта | |
CR20190252A (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
PH12016500839A1 (en) | Combination theraphy of an anti cd20 antibody with a btk inhibitor | |
CO2021006869A2 (es) | Anticuerpos humanizados contra c-kit | |
PE20180454A1 (es) | Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2 | |
UY38360A (es) | Métodos de tratamiento del cáncer | |
PE20060461A1 (es) | Combinacion de un anticuerpo her2 y gemcitabina para el tratamiento de cancer resistente al platino | |
MX2019015516A (es) | Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer. | |
MX2021000847A (es) | Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077. | |
UY39724A (es) | Método para tratar una neoplasia maligna mediante la combinación de un anticuerpo contra pd-1 y un a | |
CL2023000741A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos. | |
CL2017002275A1 (es) | Cepas bacterianas productoras de histamina y su uso en el cáncer | |
AR119681A1 (es) | Métodos de tratamiento del cáncer de mama con tucatinib | |
ZA202206993B (en) | Anti-lilrb1 antibody and uses thereof | |
DOP2023000230A (es) | Anticuerpo biespecífico anticldn4/anticd137 | |
MX2021014486A (es) | Complejo de la toxina tipo a de clostridium botulinum, formulacion y uso del mismo. | |
BR112023021913A2 (pt) | Tratamento de câncer com inibidor de raf | |
MX2021001606A (es) | Tratamiento de la malignidades de las celulas b. | |
BR112023004830A2 (pt) | Métodos para tratamento de mieloma múltiplo | |
CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres | |
AR116897A1 (es) | Métodos para tratar el cáncer con una combinación de un anticuerpo anti-vegf y un conjugado anticuerpo-fármaco anti-factor tisular | |
WO2016196373A8 (en) | Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer | |
ZA202213434B (en) | Anti-lilrb1 antibody and uses thereof |